Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An update from Shin Nippon Biomedical Laboratories, Ltd. ( (JP:2395) ) is now available.
Shin Nippon Biomedical Laboratories reported better-than-expected financial results for the first half of 2025, with revenue and interim profit surpassing forecasts due to strong CRO business performance and reduced losses from its US subsidiary. The company’s ordinary profit also exceeded expectations due to unexpected foreign exchange gains, while changes in the shipment plan of a Cambodian subsidiary led to lower income taxes, further boosting interim profit.
The most recent analyst rating on (JP:2395) stock is a Hold with a Yen1541.00 price target. To see the full list of analyst forecasts on Shin Nippon Biomedical Laboratories, Ltd. stock, see the JP:2395 Stock Forecast page.
More about Shin Nippon Biomedical Laboratories, Ltd.
Shin Nippon Biomedical Laboratories, Ltd. operates in the biomedical industry, focusing on contract research organization (CRO) services. The company is involved in various business segments, including its US subsidiary Satsuma Pharmaceuticals, Inc., and the Medipolis power generation business.
Average Trading Volume: 201,678
Technical Sentiment Signal: Sell
Current Market Cap: Yen61.57B
See more insights into 2395 stock on TipRanks’ Stock Analysis page.